JP4308918B2 - (2,6)−STエピトープクラスターを有するα−O−結合複合糖質、その製造方法および使用 - Google Patents

(2,6)−STエピトープクラスターを有するα−O−結合複合糖質、その製造方法および使用 Download PDF

Info

Publication number
JP4308918B2
JP4308918B2 JP54393498A JP54393498A JP4308918B2 JP 4308918 B2 JP4308918 B2 JP 4308918B2 JP 54393498 A JP54393498 A JP 54393498A JP 54393498 A JP54393498 A JP 54393498A JP 4308918 B2 JP4308918 B2 JP 4308918B2
Authority
JP
Japan
Prior art keywords
independently
mmol
glycoconjugate
carbohydrate
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP54393498A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002515060A5 (enExample
JP2002515060A (ja
Inventor
ジェイ ダニシェフスキー,サミュエル
セイムズ,ダリボー
ヒンターマン,サミュエル
チェン,シァオ−タオ
ビー シュワルツ,ジャコブ
グルンツ,ピーター
ラグパティ,ゴヴィンダスワミ
オー リビングストン,フィリップ
クドゥク,スコット
ウィリアムズ,ローレンス
Original Assignee
スローン−ケッタリング インスティトゥート フォア キャンサー リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スローン−ケッタリング インスティトゥート フォア キャンサー リサーチ filed Critical スローン−ケッタリング インスティトゥート フォア キャンサー リサーチ
Publication of JP2002515060A publication Critical patent/JP2002515060A/ja
Publication of JP2002515060A5 publication Critical patent/JP2002515060A5/ja
Application granted granted Critical
Publication of JP4308918B2 publication Critical patent/JP4308918B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727Mucins, e.g. human intestinal mucin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K9/00Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
JP54393498A 1997-04-16 1998-03-25 (2,6)−STエピトープクラスターを有するα−O−結合複合糖質、その製造方法および使用 Expired - Lifetime JP4308918B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4371397P 1997-04-16 1997-04-16
US60/043,713 1997-04-16
PCT/US1998/006035 WO1998046246A1 (en) 1997-04-16 1998-03-25 α-O-LINKED GLYCOCONJUGATES WITH CLUSTERED (2,6)-ST EPITOPES, METHODS OF PREPARATION AND USES THEREOF

Publications (3)

Publication Number Publication Date
JP2002515060A JP2002515060A (ja) 2002-05-21
JP2002515060A5 JP2002515060A5 (enExample) 2005-11-10
JP4308918B2 true JP4308918B2 (ja) 2009-08-05

Family

ID=21928513

Family Applications (1)

Application Number Title Priority Date Filing Date
JP54393498A Expired - Lifetime JP4308918B2 (ja) 1997-04-16 1998-03-25 (2,6)−STエピトープクラスターを有するα−O−結合複合糖質、その製造方法および使用

Country Status (6)

Country Link
US (2) US6660714B1 (enExample)
EP (1) EP0996455B1 (enExample)
JP (1) JP4308918B2 (enExample)
AU (1) AU750701C (enExample)
CA (1) CA2286798C (enExample)
WO (1) WO1998046246A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU750701C (en) 1997-04-16 2003-03-20 Sloan-Kettering Institute For Cancer Research Alpha-O-linked glycoconjugates, methods of preparation and uses thereof
US7550146B2 (en) * 1997-04-16 2009-06-23 Sloan-Kettering Institute For Cancer Research Glycopeptide conjugates and uses thereof
AU758097B2 (en) * 1998-03-25 2003-03-13 Sloan-Kettering Institute For Cancer Research Trimeric antigenic O-linked glycopeptide conjugates, methods of preparation and uses thereof
WO2001014395A2 (en) * 1999-08-20 2001-03-01 Sloan-Kettering Institute For Cancer Research Novel glycoconjugates, glycoamino, acids, intermediates thereto, and uses thereof
US7824687B2 (en) * 1999-08-20 2010-11-02 Sloan-Kettering Institute For Cancer Research Clustered multi-antigenic carbohydrate constructs, methods for their preparation, and uses thereof
US7854934B2 (en) 1999-08-20 2010-12-21 Sloan-Kettering Institute For Cancer Research Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof
WO2003003985A2 (en) 2001-07-06 2003-01-16 Sloan-Kettering Institute For Cancer Research Polyvalent conjugate vaccine for cancer
US7504364B2 (en) * 2002-03-01 2009-03-17 Receptors Llc Methods of making arrays and artificial receptors
EP1506014A4 (en) * 2002-05-20 2006-09-20 Chemstop Pty Ltd PROCESS FOR THE PRODUCTION AND ACTIVATION OF CORRESPONDING SUBSTANCES AND MEANS OF PRODUCTION
US20060057625A1 (en) * 2002-09-16 2006-03-16 Carlson Robert E Scaffold-based artificial receptors and methods
US20050136483A1 (en) * 2003-09-03 2005-06-23 Receptors Llc Nanodevices employing combinatorial artificial receptors
US20060051802A1 (en) * 2002-09-16 2006-03-09 Receptors Llc Artificial receptors, building blocks, and methods
US20050037429A1 (en) * 2003-03-28 2005-02-17 Receptors Llc Artificial receptors including reversibly immobilized building blocks and methods
US7469076B2 (en) * 2003-09-03 2008-12-23 Receptors Llc Sensors employing combinatorial artificial receptors
US20050037381A1 (en) * 2002-09-16 2005-02-17 Receptors Llc Artificial receptors, building blocks, and methods
US20040137481A1 (en) * 2002-09-16 2004-07-15 Receptors Llc Artificial receptor building blocks, components, and kits
EP1613737A4 (en) * 2003-03-28 2008-12-03 Receptors Llc ARTIFICIAL RECEPTORS COMPRISING REVERSIBLE IMMOBILIZED CONSTRUCTION BLOCKS AND METHODS
US20060035267A1 (en) * 2003-04-09 2006-02-16 Livingston Philip O Optimal polyvalent vaccine for cancer
CA2538005A1 (en) * 2003-09-05 2005-05-19 Sloan-Kettering Institute For Cancer Research Method for preparing polyfunctionalized peptides and/or proteins via native chemical ligation
US7884052B2 (en) * 2004-09-03 2011-02-08 Receptors Llc Combinatorial artificial receptors including tether building blocks on scaffolds
EP1789792A2 (en) 2004-09-11 2007-05-30 Receptors LLC Combinatorial artificial receptors including peptide building blocks
JP4942014B2 (ja) * 2004-09-14 2012-05-30 独立行政法人産業技術総合研究所 O−結合型糖アミノ酸
ATE509027T1 (de) 2006-01-13 2011-05-15 Pasteur Institut Enzymatische synthese von grossen mengen von mucin glyconjugaten und deren immunogenische anwendungen
CA2649303C (en) 2006-04-11 2016-09-27 Sloan-Kettering Institute For Cancer Research Homogeneous erythropoietin and other peptides and proteins, methods and intermediates for their preparation
MX2010013931A (es) 2008-06-16 2011-06-01 Academia Sinica Diagnosis de cancer basada en niveles de anticuerpos contra globo h y sus fragmentos.
CA2728344A1 (en) * 2008-06-16 2010-01-14 Academia Sinica Compositions for inducing immune responses specific to globo h and ssea3 and uses thereof in cancer treatment
WO2010006343A2 (en) * 2008-07-11 2010-01-14 Sloan-Kettering Institute For Cancer Research Glycopeptide constructs and uses thereof
CN102215862B (zh) * 2009-06-16 2016-04-06 中央研究院 Globo h及含新颖糖脂质佐剂的相关抗癌疫苗
CN103108654A (zh) 2010-06-11 2013-05-15 索隆-基特林癌症研究协会 多价糖肽构建体及其用途
EP2500033A1 (en) * 2011-03-17 2012-09-19 Institut Pasteur Method for preparing muliple antigen glycopeptide carbohydrate conjugates
EP2912182B1 (en) 2012-10-23 2021-12-08 Caris Science, Inc. Aptamers and uses thereof
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
WO2014100434A1 (en) 2012-12-19 2014-06-26 Caris Science, Inc. Compositions and methods for aptamer screening
US10155823B2 (en) 2014-08-22 2018-12-18 Academia Sinica Glycan conjugates and use thereof
PT110526B (pt) 2018-01-26 2021-02-04 Univ Nova De Lisboa Anticorpo, fragmento funcional ou sonda do mesmo contra antigénios tumorais
CN111303112A (zh) * 2020-02-28 2020-06-19 南京工业大学 一种固定二氧化碳的方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4971795A (en) 1986-07-08 1990-11-20 Biomira, Inc. Enhancement of the cellular immune response using carbohydrate primed DTH effector cells expressing the CD5+/CD8- phenotype
US6054438A (en) 1987-01-07 2000-04-25 Imperial Cancer Research Technology Limited Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin
JPH02501828A (ja) 1987-01-07 1990-06-21 インペリアル・キヤンサー・リサーチ・テクノロジー・リミテツド プローブ
US5683674A (en) 1987-01-07 1997-11-04 Imperial Cancer Research Technology Ltd. Antibody against human mucin core protein and method of preparing and using same
US5053489A (en) 1988-01-29 1991-10-01 Dana-Farber Cancer Institute, Inc. Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US5229289A (en) 1988-03-11 1993-07-20 The Biomembrane Institute Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with animal and human and with synthetic carbohydrate-carrier conjugates
US5660834A (en) 1988-03-11 1997-08-26 The Biomembrane Institute Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with carbohydrate-carrier conjugates
EP0395217A3 (en) 1989-04-28 1991-01-23 The Biomembrane Institute Bio-organic synthesis of dimeric lex (difucosyl y2; iii3fucv3-funcnlc6cer) and analogues thereof
IL94872A (en) 1989-06-30 1995-03-30 Oncogen Monoclonal or chimeric antibodies reactive with human carcinomas, recombinant proteins comprising their antigen binding region, pharmaceutical compositions and kits comprising said antibodies and methods for imaging human carcinoma using same
US5212298A (en) 1989-08-16 1993-05-18 Monsanto Company Method for producing synthetic N-linked glycoconjugates
US5280113A (en) 1989-08-16 1994-01-18 Monsanto Company Method for producing synthetic N-linked glycoconjugates
IL105503A (en) * 1992-04-28 1999-05-09 Astra Ab Carbon peptide couplets capable of eliciting an immune response of T cells
US5376531A (en) 1992-09-03 1994-12-27 Northwestern University Method of detecting cancer
WO1995018781A1 (en) 1994-01-06 1995-07-13 Metabolix, Inc. Methods for synthesizing oligomers containing hydroxy acid units
US5708163A (en) 1994-03-15 1998-01-13 Sloan-Kettering Institute Of Cancer Research Synthesis of the breast tumor-associated antigen defined by monoclonalantibody MBRL and uses thereof
US5679769A (en) * 1994-03-15 1997-10-21 Sloan-Kettering Institute For Cancer Research Synthesis of asparagine-linked glycopeptides on a polymeric solid support
US6303120B1 (en) 1994-03-15 2001-10-16 Memorial Sloan-Kettering Institute For Cancer Research Synthesis of glycoconjugates of the lewis y epitope and uses thereof
CA2189356A1 (en) 1994-05-02 1995-11-09 Ting Chi Wong Process for preparation of glycosides of tumor-associated carbohydrate antigens
DE4436164A1 (de) 1994-10-10 1996-04-11 Hoechst Ag Neue Kohlenhydratkonjugate als Inhibitoren der Zelladhäsion
JP3139957B2 (ja) 1995-03-17 2001-03-05 財団法人神奈川科学技術アカデミー レクチンの固定化法及びそれを用いた細胞用基材
US5871990A (en) 1996-05-15 1999-02-16 Clausen; Henrik UDP-N-acetyl-α-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase, gAlnAc-T3
AU747899B2 (en) 1997-01-13 2002-05-30 Sloan-Kettering Institute For Cancer Research Colon cancer KH-1 and N3 antigens
US7550146B2 (en) 1997-04-16 2009-06-23 Sloan-Kettering Institute For Cancer Research Glycopeptide conjugates and uses thereof
AU750701C (en) 1997-04-16 2003-03-20 Sloan-Kettering Institute For Cancer Research Alpha-O-linked glycoconjugates, methods of preparation and uses thereof
CA2304599A1 (en) 1997-09-25 1999-04-01 Sloan-Kettering Institute For Cancer Research Fucosyl gm1-klh conjugate vaccine against small cell lung cancer
AU758097B2 (en) 1998-03-25 2003-03-13 Sloan-Kettering Institute For Cancer Research Trimeric antigenic O-linked glycopeptide conjugates, methods of preparation and uses thereof
WO2001014395A2 (en) 1999-08-20 2001-03-01 Sloan-Kettering Institute For Cancer Research Novel glycoconjugates, glycoamino, acids, intermediates thereto, and uses thereof
US7854934B2 (en) 1999-08-20 2010-12-21 Sloan-Kettering Institute For Cancer Research Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof
US7824687B2 (en) 1999-08-20 2010-11-02 Sloan-Kettering Institute For Cancer Research Clustered multi-antigenic carbohydrate constructs, methods for their preparation, and uses thereof

Also Published As

Publication number Publication date
AU750701B2 (en) 2002-07-25
US20030083235A1 (en) 2003-05-01
AU6779298A (en) 1998-11-11
EP0996455A4 (en) 2005-06-08
CA2286798A1 (en) 1998-10-22
US6660714B1 (en) 2003-12-09
WO1998046246A1 (en) 1998-10-22
AU750701C (en) 2003-03-20
CA2286798C (en) 2014-01-07
JP2002515060A (ja) 2002-05-21
EP0996455A1 (en) 2000-05-03
US7160856B2 (en) 2007-01-09
EP0996455B1 (en) 2009-12-16

Similar Documents

Publication Publication Date Title
JP4308918B2 (ja) (2,6)−STエピトープクラスターを有するα−O−結合複合糖質、その製造方法および使用
AU758097B2 (en) Trimeric antigenic O-linked glycopeptide conjugates, methods of preparation and uses thereof
US6303120B1 (en) Synthesis of glycoconjugates of the lewis y epitope and uses thereof
JP5484668B2 (ja) モノクローナル抗体mbr1によって同定される乳ガン関連抗原の合成及びこれらの使用
US6544952B1 (en) Synthesis of glycoconjugates of the globo-H epitope and uses thereof
WO1996040198A1 (en) Synthesis of asparagine-linked glycopeptides on a polymeric solid support
JP5111705B2 (ja) 新規な複合多糖、グリコアミノ酸、これらへの中間体、及びこれらの使用
US7550146B2 (en) Glycopeptide conjugates and uses thereof
AU747899B2 (en) Colon cancer KH-1 and N3 antigens

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070619

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070919

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20071029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090213

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090407

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090507

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120515

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120515

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130515

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140515

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term